Mechanisms, Clinical Benefits, Safety Monitoring, and Nursing Considerations
Introduction
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are a rapidly expanding class of incretin-based therapies originally developed for the management of type 2 diabetes mellitus (T2DM). Their clinical applications have expanded significantly due to their beneficial effects on weight management, cardiovascular risk reduction, and metabolic disease modification.¹
GLP-1 receptor agonists mimic the activity of endogenous glucagon-like peptide-1 (GLP-1), an intestinal hormone released after food intake. Physiologically, GLP-1 regulates glucose metabolism, appetite, and gastrointestinal function by acting on multiple organs, including the pancreas, gastrointestinal tract, brain, and cardiovascular system.¹,²
For nurses, knowledge of GLP-1 receptor agonists is
increasingly important because nurses have a central role in:
• Patient education
• Medication administration and injection training
• Monitoring treatment response
• Recognizing adverse effects
• Supporting adherence
• Identifying complications requiring medical evaluation
1. Pharmacological Background and Mechanism of Action
1.1 The GLP-1 System
Endogenous GLP-1 is secreted primarily by intestinal L-cells following nutrient ingestion. It acts as an incretin hormone by enhancing insulin secretion in response to elevated blood glucose levels.¹
However, natural GLP-1 has a very short biological half-life because it is rapidly degraded by dipeptidyl peptidase-4 (DPP-4). GLP-1 receptor agonists were developed as longer-acting molecules capable of producing sustained metabolic effects.²
1.2 Pancreatic Effects
Enhancement of Insulin Secretion
GLP-1 receptor activation on pancreatic β-cells
increases insulin secretion.
A major pharmacological advantage is that this effect is glucose dependent.
Therefore:
• Insulin secretion increases mainly when glucose levels are elevated
• Risk of hypoglycemia is relatively low when GLP-1 RAs are used alone¹
However, hypoglycemia risk increases when combined
with:
• Insulin
• Sulfonylureas
Nursing considerations
Monitor for symptoms of hypoglycemia:
• Sweating
• Tremor
• Palpitations
• Confusion
• Dizziness
Suppression of Glucagon Secretion
GLP-1 receptor activation suppresses pancreatic α-cell glucagon secretion during hyperglycemia.
Reduced glucagon results in:
↓ Hepatic glucose production
↓ Fasting glucose concentration
2. Gastrointestinal Effects
Delayed Gastric Emptying
GLP-1 receptor agonists slow gastric emptying,
resulting in:
• Reduced postprandial glucose elevation
• Increased gastric fullness
• Reduced appetite
Common symptoms include:
• Nausea
• Vomiting
• Abdominal discomfort
• Constipation
• Diarrhea
• Early satiety
3. Central Nervous System Effects and Appetite Regulation
GLP-1 receptors are expressed in brain regions involved in appetite regulation, including hypothalamic pathways.
Activation produces:
↑ Satiety signals
↓ Hunger perception
4. Clinical Benefits of GLP-1 Receptor Agonists
4.1 Glycemic Control
GLP-1 receptor agonists improve:
• Fasting glucose
• Postprandial glucose
• HbA1c levels
4.2 Weight Reduction
Weight loss occurs through:
• Reduced appetite
• Increased satiety
• Delayed gastric emptying
4.3 Cardiovascular Benefits
Several cardiovascular outcome trials (CVOTs) have demonstrated cardiovascular benefits.
LEADER Trial
Liraglutide reduced major cardiovascular events.⁵
SUSTAIN-6 Trial
Semaglutide reduced MACE (major adverse cardiovascular events).⁶
REWIND Trial
Dulaglutide reduced cardiovascular events.⁷
4.4 Kidney and Liver Effects
Potential benefits include:
• Reduced albuminuria
• Slower kidney function decline
• Reduced hepatic steatosis
5. Available GLP-1 Receptor Agonists
• Liraglutide
• Semaglutide
• Dulaglutide
• Exenatide
6. Adverse Effects and Safety Monitoring
Common Adverse Effects
Primarily gastrointestinal:
• Nausea
• Vomiting
• Constipation
• Diarrhea
6.1 Gallbladder Disease
Risk of cholelithiasis and cholecystitis
6.2 Pancreatitis
Rare but clinically significant risk.
6.3 Diabetic Retinopathy
Rapid improvement in glycemic control may transiently worsen retinopathy.
6.4 Dehydration and Acute Kidney Injury
Risk increased in:
• Older adults
• Patients with renal impairment
7. Contraindications and Precautions
Avoid or use cautiously in:
• Medullary thyroid carcinoma risk
• Multiple endocrine neoplasia type 2 (MEN2)
• Severe gastrointestinal motility disorders
• Advanced kidney disease
8. Nursing Responsibilities in Clinical Practice
Patient Education
• Expected therapeutic effects
• Possible gastrointestinal symptoms
• Importance of adherence
Injection Education
• Injection technique
• Site rotation
• Storage requirements
Monitoring
• Blood glucose
• HbA1c trends
• Body weight
• Hydration status
• Adverse effects
9. Long-Term Treatment Considerations
Discontinuation may result in:
• Increased appetite
• Weight regains
• Loss of metabolic control
10. Future Directions
• Dual incretin therapies (GLP-1/GIP)
• Oral peptide formulations
• Expanded cardiometabolic indications
Conclusion
GLP-1 receptor agonists represent integrated cardiometabolic therapies that improve glycemic control, reduce weight, and provide cardiovascular benefits. Nursing practice is central to safe and effective long-term use.
References:
1.Drucker DJ. Mechanisms of Action and Therapeutic Application of Glucagon-Like Peptide-1 Receptor Agonists. Cell Metab. 2018;27(4):740–756.
2.Ussher JR, Drucker DJ. Glucagon-Like Peptide-1 Receptor Agonists: Cardiovascular Benefits and Mechanisms of Action. Nat Rev Cardiol. 2023;20:463–474.
3.Nauck MA, Quast DR, Wefers J, Meier JJ. GLP-1 Receptor Agonists in the Treatment of Type 2 Diabetes-stat-of-the-art. Diabetologia. 2021;64:1205–1218.
4.Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384:989–1002.
5.Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2016;375:311–322.
6.Marso SP, Bain SC, Consoli A, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2016;375:1834–1844.
7.Gerstein HC, Colhoun HM, Dagenais GR, et al. Dulaglutide and Cardiovascular Outcomes in Type 2 Diabetes (REWIND Trial). Lancet. 2019;394:121–130.
8.Kristensen SL, Rørth R, Jhund PS, et al. Cardiovascular, Mortality, and Kidney Outcomes with GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis. Lancet Diabetes Endocrinol. 2019;7:776–785
